Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial

A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia

(2019) Rosa Nguyen et al.   Journal for ImmunoTherapy of Cancer

The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma

(2018) Rosa Nguyen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Ex Vivo Expanded Human NK Cells Survive and Proliferate in Humanized Mice with Autologous Human Immune Cells

(2017) Fatemeh Vahedi et al.   Scientific Reports

KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma

(2016) Christopher J. Forlenza et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study.

(2016) Julie R. Park et al.   JOURNAL OF CLINICAL ONCOLOGY

NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia

(2010) Jeffrey E. Rubnitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy

(2009) H. Fujisaki et al.   CANCER RESEARCH